Lars Gösta Jonsson

BioPhausia AB operates as a pharmaceutical company. It markets and distributes original drugs, generic products, and the parallel-imported medicines. The company is headquartered in Stockholm, Sweden.

Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds.

Mando AB engages in the provision of health care services. It offers treatment for anorexia nervosa and bulimia nervosa as well as other eating disorders using Mandometer Method. The company was founded in 2000 and is headquartered in Huddinge, Sweden.

KDev Exploratory AB provides drug discovery solutions. It performs discovery research in various therapeutic areas, such as screening in oncology, neuroscience, lead finding, characterization in inflammation and angiogenesis/age-related macular degeneration. The company was founded by David Jern in 2000 and is headquartered in Solna, Sweden.